European Psychiatry, ISSN 0924-9338, 11/2015, Volume 30, Issue 8, p. S135-S136
Les troubles du spectre autistique (TSA) sont des troubles neuro-developpementaux invalidants avec une grande heterogeneite clinique. Beaucoup de patients avec...
Clozapine
Clozapine
Journal Article
Pharmacogenomics, ISSN 1462-2416, 01/2014, Volume 15, Issue 1, pp. 95 - 110
Schizophrenia is a severe disorder that significantly affects the quality of life and total functioning of patients and their caregivers. Clozapine is the...
Clozapine
Clozapine
Journal Article
Pharmacogenomics, ISSN 1462-2416, 11/2013, Volume 14, Issue 15, pp. 1907 - 1914
Clozapine is a uniquely efficacious antipsychotic drug in treatment-resistant schizophrenia. Its use is restricted due to adverse effects including a rare but...
Clozapine
Clozapine
Journal Article
Pharmacogenomics, ISSN 1462-2416, 11/2013, Volume 14, Issue 15, pp. 1907 - 1914
Clozapine is a uniquely efficacious antipsychotic drug in treatment-resistant schizophrenia. Its use is restricted due to adverse effects including a rare but...
Clozapine
Clozapine
Journal Article
Science, ISSN 0036-8075, 08/2017, Volume 357, Issue 6350, pp. 503 - 507
The chemogenetic technology DREADD (designer receptors exclusively activated by designer drugs) is widely used for remote manipulation of neuronal activity in...
N-OXIDE | METABOLISM | RAT | MULTIDISCIPLINARY SCIENCES | IN-VIVO | DRUGS | MICE | BLOOD-BRAIN-BARRIER | Binding, Competitive | Designer Drugs - administration & dosage | Designer Drugs - pharmacology | Clozapine - administration & dosage | Humans | Receptor, Muscarinic M3 - metabolism | Mice, Transgenic | Receptor, Muscarinic M4 - metabolism | Clozapine - analogs & derivatives | Genetic Techniques | Brain - drug effects | Brain - metabolism | Clozapine - pharmacology | Animals | HEK293 Cells | Designer Drugs - pharmacokinetics | Mice | Neurons - drug effects | Clozapine - pharmacokinetics | Dosage and administration | Genetic aspects | Clozapine | Gene expression | Observations | Drug interactions | Drugs | Brain | Receptors | Technology | Central nervous system | Positron emission | Emission measurements | Affinity | Positron emission tomography
N-OXIDE | METABOLISM | RAT | MULTIDISCIPLINARY SCIENCES | IN-VIVO | DRUGS | MICE | BLOOD-BRAIN-BARRIER | Binding, Competitive | Designer Drugs - administration & dosage | Designer Drugs - pharmacology | Clozapine - administration & dosage | Humans | Receptor, Muscarinic M3 - metabolism | Mice, Transgenic | Receptor, Muscarinic M4 - metabolism | Clozapine - analogs & derivatives | Genetic Techniques | Brain - drug effects | Brain - metabolism | Clozapine - pharmacology | Animals | HEK293 Cells | Designer Drugs - pharmacokinetics | Mice | Neurons - drug effects | Clozapine - pharmacokinetics | Dosage and administration | Genetic aspects | Clozapine | Gene expression | Observations | Drug interactions | Drugs | Brain | Receptors | Technology | Central nervous system | Positron emission | Emission measurements | Affinity | Positron emission tomography
Journal Article
Progress in Neurology and Psychiatry, ISSN 1367-7543, 05/2014, Volume 18, Issue 3, pp. 20 - 20
Journal Article
The Brown University Psychopharmacology Update, ISSN 1068-5308, 09/2016, Volume 27, Issue 9, p. 8
Journal Article
Psychopharmacology, ISSN 0033-3158, 2/2013, Volume 225, Issue 3, pp. 505 - 518
Clozapine levels are advocated in the monitoring of patients on this drug and have now been used for a number of years. A safety-related threshold has also...
Therapeutic threshold | Antipsychotics | Neurosciences | Side effects | Biomedicine | Toxicity | Pharmacology/Toxicology | Clozapine levels | Psychiatry | Safety-related threshold | PSYCHIATRY | FLUVOXAMINE | RECEPTOR OCCUPANCY | LEVEL | NEUROSCIENCES | PLASMA CLOZAPINE | PHARMACOKINETICS | PREDICTORS | SERUM-LEVELS | PHARMACOLOGY & PHARMACY | HIGH-DOSE CLOZAPINE | CHILDHOOD-ONSET SCHIZOPHRENIA | CLINICAL-RESPONSE | Antipsychotic Agents - administration & dosage | Dose-Response Relationship, Drug | Antipsychotic Agents - blood | Antipsychotic Agents - adverse effects | Clozapine - administration & dosage | Clozapine - blood | Clozapine - adverse effects | Drug Monitoring | Databases, Factual | Measurement | Clozapine | Research | Standards | Psychotropic drugs | Psychopharmacology | Index Medicus | Drugs | Case reports | Clinical trials | Data processing | Myocarditis | Serum levels | Databases | Antidepressants | Plasma levels | Pharmacokinetics | Heart diseases | Neutropenia | Seizures | Smoking
Therapeutic threshold | Antipsychotics | Neurosciences | Side effects | Biomedicine | Toxicity | Pharmacology/Toxicology | Clozapine levels | Psychiatry | Safety-related threshold | PSYCHIATRY | FLUVOXAMINE | RECEPTOR OCCUPANCY | LEVEL | NEUROSCIENCES | PLASMA CLOZAPINE | PHARMACOKINETICS | PREDICTORS | SERUM-LEVELS | PHARMACOLOGY & PHARMACY | HIGH-DOSE CLOZAPINE | CHILDHOOD-ONSET SCHIZOPHRENIA | CLINICAL-RESPONSE | Antipsychotic Agents - administration & dosage | Dose-Response Relationship, Drug | Antipsychotic Agents - blood | Antipsychotic Agents - adverse effects | Clozapine - administration & dosage | Clozapine - blood | Clozapine - adverse effects | Drug Monitoring | Databases, Factual | Measurement | Clozapine | Research | Standards | Psychotropic drugs | Psychopharmacology | Index Medicus | Drugs | Case reports | Clinical trials | Data processing | Myocarditis | Serum levels | Databases | Antidepressants | Plasma levels | Pharmacokinetics | Heart diseases | Neutropenia | Seizures | Smoking
Journal Article
Schizophrenia Research, ISSN 0920-9964, 11/2009, Volume 115, Issue 1, p. 96
Journal Article
10.
Full Text
6. Altered RNA Editing and Behavior in Prenatally Stressed Mice are Reversed by Clozapine
Journal Article
Physiology & Behavior, ISSN 0031-9384, 10/2017, Volume 179, p. 346
Cognitive impairment associated with schizophrenia (CIAS) is highly prevalent and affects the overall functioning of patients. Clozapine (Clz), an atypical...
Schizophrenia | Clozapine
Schizophrenia | Clozapine
Journal Article
Forensic Science International, ISSN 0379-0738, 2011, Volume 214, Issue 1, pp. e23 - e25
Abstract Clozapine is a uniquely effective antipsychotic, but is very toxic in clozapine-naïve subjects. A 34-year-old male patient in a mental health...
Pathology | Clozapine: post mortem toxicology | Clozapine: sudden death | Clozapine toxicity: naïve subjects | PLASMA CLOZAPINE | Clozapine toxicity: naive subjects | MEDICINE, LEGAL | NORCLOZAPINE | TOXICITY | Antipsychotic Agents - blood | Fatty Liver - pathology | Obesity - complications | Antipsychotic Agents - adverse effects | Clozapine - administration & dosage | Humans | Male | Clozapine - analogs & derivatives | Antipsychotic Agents - administration & dosage | Hypertrophy, Left Ventricular - pathology | Fatal Outcome | Adult | Clozapine - blood | Clozapine - adverse effects | Causes of | Clozapine | Analysis | Sudden death | Psychotropic drugs | Plasma | Obesity | Toxicity | Drug dosages | Drugs | Death | Risk | Adults | Fatal | Patients | Blood | Ingestion | Index Medicus
Pathology | Clozapine: post mortem toxicology | Clozapine: sudden death | Clozapine toxicity: naïve subjects | PLASMA CLOZAPINE | Clozapine toxicity: naive subjects | MEDICINE, LEGAL | NORCLOZAPINE | TOXICITY | Antipsychotic Agents - blood | Fatty Liver - pathology | Obesity - complications | Antipsychotic Agents - adverse effects | Clozapine - administration & dosage | Humans | Male | Clozapine - analogs & derivatives | Antipsychotic Agents - administration & dosage | Hypertrophy, Left Ventricular - pathology | Fatal Outcome | Adult | Clozapine - blood | Clozapine - adverse effects | Causes of | Clozapine | Analysis | Sudden death | Psychotropic drugs | Plasma | Obesity | Toxicity | Drug dosages | Drugs | Death | Risk | Adults | Fatal | Patients | Blood | Ingestion | Index Medicus
Journal Article
Sensors & Actuators: B. Chemical, ISSN 0925-4005, 03/2017, Volume 241, p. 879
Journal Article
Neuropharmacology, ISSN 0028-3908, 02/2007, Volume 52, Issue 2, p. 387
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 03/2017, Volume 2017, Issue 3, p. CD006324
Background Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a...
Risperidone [therapeutic use] | REFRACTORY SCHIZOPHRENIA | EFFICACY | Humans | STATISTICS NOTES | Male | RISPERIDONE | MEDICINE, GENERAL & INTERNAL | Schizophrenia [drug therapy] | Thiazoles [therapeutic use] | Female | Clozapine [adverse effects; therapeutic use] | Sulpiride [analogs & derivatives; therapeutic use] | Drug Resistance | Dibenzothiazepines [therapeutic use] | Antipsychotic Agents [adverse effects; therapeutic use] | AUGMENTATION | Quetiapine Fumarate | DrugTherapy, Combination | NETWORK METAANALYSIS | Randomized Controlled Trials as Topic | ARIPIPRAZOLE-CLOZAPINE | SUBOPTIMAL RESPONSE | DOUBLE-BLIND | RATING-SCALE | Piperazines [therapeutic use] | Clozapine - therapeutic use | Antipsychotic Agents - adverse effects | Amisulpride | Thiazoles - therapeutic use | Aripiprazole - adverse effects | Sulpiride - analogs & derivatives | Dibenzothiazepines - therapeutic use | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Aripiprazole - therapeutic use | Adult | Drug Therapy, Combination | Weight Gain | Sulpiride - adverse effects | Sulpiride - therapeutic use | Haloperidol - therapeutic use | Piperazines - therapeutic use | Haloperidol - adverse effects | Schizophrenia - drug therapy | Clozapine - adverse effects
Risperidone [therapeutic use] | REFRACTORY SCHIZOPHRENIA | EFFICACY | Humans | STATISTICS NOTES | Male | RISPERIDONE | MEDICINE, GENERAL & INTERNAL | Schizophrenia [drug therapy] | Thiazoles [therapeutic use] | Female | Clozapine [adverse effects; therapeutic use] | Sulpiride [analogs & derivatives; therapeutic use] | Drug Resistance | Dibenzothiazepines [therapeutic use] | Antipsychotic Agents [adverse effects; therapeutic use] | AUGMENTATION | Quetiapine Fumarate | DrugTherapy, Combination | NETWORK METAANALYSIS | Randomized Controlled Trials as Topic | ARIPIPRAZOLE-CLOZAPINE | SUBOPTIMAL RESPONSE | DOUBLE-BLIND | RATING-SCALE | Piperazines [therapeutic use] | Clozapine - therapeutic use | Antipsychotic Agents - adverse effects | Amisulpride | Thiazoles - therapeutic use | Aripiprazole - adverse effects | Sulpiride - analogs & derivatives | Dibenzothiazepines - therapeutic use | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Aripiprazole - therapeutic use | Adult | Drug Therapy, Combination | Weight Gain | Sulpiride - adverse effects | Sulpiride - therapeutic use | Haloperidol - therapeutic use | Piperazines - therapeutic use | Haloperidol - adverse effects | Schizophrenia - drug therapy | Clozapine - adverse effects
Journal Article
Pharmacopsychiatry, ISSN 0176-3679, 01/2015, Volume 48, Issue 1, pp. 11 - 14
Abstract Abstract Introduction: The clinical records of 190 patients with schizophrenia who discontinued clozapine between 1990 and 2012 in the county of...
Original Paper | clozapine discontinuation | olanzapine | schizophrenia past clozapine | alternative to clozapine | clozapine mortality
Original Paper | clozapine discontinuation | olanzapine | schizophrenia past clozapine | alternative to clozapine | clozapine mortality
Journal Article
Journal of Clinical Psychopharmacology, ISSN 0271-0749, 10/2018, Volume 38, Issue 5, pp. 442 - 446
Purpose/Background Some therapeutic drug monitoring studies suggest that increased weight is associated with small increases in clozapine concentrations. The...
adipose tissue | clozapine, pharmacokinetics | clozapine, blood | obesity | weight gain | LONG-TERM | EFFECTS LINEAR-MODELS | PSYCHIATRY | SCHIZOPHRENIA | SMOKING | blood | INDIVIDUALIZATION | pharmacokinetics | clozapine | PHARMACOLOGY & PHARMACY | VARIABLES | NORCLOZAPINE | ASSOCIATION | DRUG-MONITORING SERVICE | Clozapine - therapeutic use | Double-Blind Method | Antipsychotic Agents - blood | Humans | Middle Aged | Body Weight - drug effects | Male | Weight Gain - physiology | Models, Statistical | Adipose Tissue - metabolism | Clozapine - pharmacology | Antipsychotic Agents - therapeutic use | Data Analysis | Adult | Female | Weight Gain - drug effects | Clozapine - blood | Antipsychotic Agents - pharmacology | Body Weight - physiology | Adipose Tissue - drug effects
adipose tissue | clozapine, pharmacokinetics | clozapine, blood | obesity | weight gain | LONG-TERM | EFFECTS LINEAR-MODELS | PSYCHIATRY | SCHIZOPHRENIA | SMOKING | blood | INDIVIDUALIZATION | pharmacokinetics | clozapine | PHARMACOLOGY & PHARMACY | VARIABLES | NORCLOZAPINE | ASSOCIATION | DRUG-MONITORING SERVICE | Clozapine - therapeutic use | Double-Blind Method | Antipsychotic Agents - blood | Humans | Middle Aged | Body Weight - drug effects | Male | Weight Gain - physiology | Models, Statistical | Adipose Tissue - metabolism | Clozapine - pharmacology | Antipsychotic Agents - therapeutic use | Data Analysis | Adult | Female | Weight Gain - drug effects | Clozapine - blood | Antipsychotic Agents - pharmacology | Body Weight - physiology | Adipose Tissue - drug effects
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 06/2015, Volume 172, Issue 6, pp. 579 - 585
Objective:Clozapine’s potent antagonism of muscarinic M1 receptors is thought to worsen working memory deficits associated with schizophrenia. In contrast, its...
EFFICACY | PSYCHIATRY | MUSCARINIC RECEPTORS | OLDER-ADULTS | INVOLVEMENT | DOUBLE-BLIND | NORCLOZAPINE | RELIABILITY | RISPERIDONE | COGNITION | SERUM ANTICHOLINERGICITY | Clozapine - therapeutic use | Psychotic Disorders - diagnosis | Schizophrenia - blood | Humans | Middle Aged | Psychotic Disorders - psychology | Male | Memory, Short-Term - drug effects | Psychometrics | Treatment Outcome | Clozapine - analogs & derivatives | Psychotic Disorders - blood | Young Adult | Neuropsychological Tests - statistics & numerical data | Schizophrenia - diagnosis | Adult | Female | Aged | Clozapine - blood | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Clozapine - adverse effects | Clozapine - pharmacokinetics
EFFICACY | PSYCHIATRY | MUSCARINIC RECEPTORS | OLDER-ADULTS | INVOLVEMENT | DOUBLE-BLIND | NORCLOZAPINE | RELIABILITY | RISPERIDONE | COGNITION | SERUM ANTICHOLINERGICITY | Clozapine - therapeutic use | Psychotic Disorders - diagnosis | Schizophrenia - blood | Humans | Middle Aged | Psychotic Disorders - psychology | Male | Memory, Short-Term - drug effects | Psychometrics | Treatment Outcome | Clozapine - analogs & derivatives | Psychotic Disorders - blood | Young Adult | Neuropsychological Tests - statistics & numerical data | Schizophrenia - diagnosis | Adult | Female | Aged | Clozapine - blood | Psychotic Disorders - drug therapy | Schizophrenia - drug therapy | Clozapine - adverse effects | Clozapine - pharmacokinetics
Journal Article
Forensic Science International, ISSN 0379-0738, 2010, Volume 206, Issue 1, pp. e31 - e36
Abstract Aim To highlight some problems that may occur when investigating clozapine-associated deaths including (i) that death may be related to...
Pathology | Clozapine: paralytic ileus | Clozapine: gastrointestinal hypomotility | Clozapine: interpretation of post-mortem toxicology | PLASMA CLOZAPINE | INDUCED CONSTIPATION | THERAPY | COLITIS | MEDICINE, LEGAL | NORCLOZAPINE | OLANZAPINE | OF-THE-LITERATURE | BLOOD | Lung - pathology | Intestines - pathology | Antipsychotic Agents - blood | Antipsychotic Agents - adverse effects | Brain Edema - pathology | Humans | Gastrointestinal Motility - drug effects | Male | Clozapine - analogs & derivatives | Constipation - complications | Constipation - chemically induced | Intestinal Pseudo-Obstruction - chemically induced | Adult | Pulmonary Edema - pathology | Clozapine - blood | Clozapine - adverse effects | Spleen - pathology | Respiratory Aspiration - etiology | Psychotropic drugs | Inflammatory bowel disease | Hospitals | Metabolites | Mortality | Laxatives | Drug dosages | Constipation | Abdomen | Index Medicus | Fouling | Fluid dynamics | Forensic science | Fluid flow | Death | Mucus | Assessments | Patients | Blood
Pathology | Clozapine: paralytic ileus | Clozapine: gastrointestinal hypomotility | Clozapine: interpretation of post-mortem toxicology | PLASMA CLOZAPINE | INDUCED CONSTIPATION | THERAPY | COLITIS | MEDICINE, LEGAL | NORCLOZAPINE | OLANZAPINE | OF-THE-LITERATURE | BLOOD | Lung - pathology | Intestines - pathology | Antipsychotic Agents - blood | Antipsychotic Agents - adverse effects | Brain Edema - pathology | Humans | Gastrointestinal Motility - drug effects | Male | Clozapine - analogs & derivatives | Constipation - complications | Constipation - chemically induced | Intestinal Pseudo-Obstruction - chemically induced | Adult | Pulmonary Edema - pathology | Clozapine - blood | Clozapine - adverse effects | Spleen - pathology | Respiratory Aspiration - etiology | Psychotropic drugs | Inflammatory bowel disease | Hospitals | Metabolites | Mortality | Laxatives | Drug dosages | Constipation | Abdomen | Index Medicus | Fouling | Fluid dynamics | Forensic science | Fluid flow | Death | Mucus | Assessments | Patients | Blood
Journal Article